| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 11277292
[patent_doc_number] => 09493769
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-11-15
[patent_title] => 'Yeast-based assay for measuring the functional activity of an HIV-1 protease in response to an antiviral agent'
[patent_app_type] => utility
[patent_app_number] => 12/504456
[patent_app_country] => US
[patent_app_date] => 2009-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 6
[patent_no_of_words] => 9023
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 379
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12504456
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/504456 | Yeast-based assay for measuring the functional activity of an HIV-1 protease in response to an antiviral agent | Jul 15, 2009 | Issued |
Array
(
[id] => 6245610
[patent_doc_number] => 20100135994
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-06-03
[patent_title] => 'HIV VACCINE BASED ON TARGETING MAXIMIZED GAG AND NEF TO DENDRITIC CELLS'
[patent_app_type] => utility
[patent_app_number] => 12/504463
[patent_app_country] => US
[patent_app_date] => 2009-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 26
[patent_no_of_words] => 16025
[patent_no_of_claims] => 62
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0135/20100135994.pdf
[firstpage_image] =>[orig_patent_app_number] => 12504463
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/504463 | Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef | Jul 15, 2009 | Issued |
Array
(
[id] => 6588704
[patent_doc_number] => 20100061991
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-03-11
[patent_title] => 'Identification of therapeutic agents for HIV infection'
[patent_app_type] => utility
[patent_app_number] => 12/457673
[patent_app_country] => US
[patent_app_date] => 2009-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 15297
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0061/20100061991.pdf
[firstpage_image] =>[orig_patent_app_number] => 12457673
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/457673 | Identification of therapeutic agents for HIV infection | Jun 17, 2009 | Abandoned |
Array
(
[id] => 6543989
[patent_doc_number] => 20100016225
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-01-21
[patent_title] => 'CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY'
[patent_app_type] => utility
[patent_app_number] => 12/478310
[patent_app_country] => US
[patent_app_date] => 2009-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 13740
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0016/20100016225.pdf
[firstpage_image] =>[orig_patent_app_number] => 12478310
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/478310 | CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY | Jun 3, 2009 | Abandoned |
Array
(
[id] => 5302864
[patent_doc_number] => 20090297516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-12-03
[patent_title] => 'ENGINEERED LECTINS FOR VIRAL INACTIVATION'
[patent_app_type] => utility
[patent_app_number] => 12/476660
[patent_app_country] => US
[patent_app_date] => 2009-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 25819
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0297/20090297516.pdf
[firstpage_image] =>[orig_patent_app_number] => 12476660
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/476660 | Engineered lectin oligomers with antiviral activity | Jun 1, 2009 | Issued |
Array
(
[id] => 6290044
[patent_doc_number] => 20100158938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-06-24
[patent_title] => 'Tetravalent Dengue Vaccines'
[patent_app_type] => utility
[patent_app_number] => 12/471962
[patent_app_country] => US
[patent_app_date] => 2009-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 32796
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0158/20100158938.pdf
[firstpage_image] =>[orig_patent_app_number] => 12471962
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/471962 | Tetravalent Dengue Vaccines | May 25, 2009 | Abandoned |
Array
(
[id] => 6588136
[patent_doc_number] => 20100291540
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-11-18
[patent_title] => 'CARBOHYDRATE BINDING MODULE AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/464788
[patent_app_country] => US
[patent_app_date] => 2009-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 4138
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0291/20100291540.pdf
[firstpage_image] =>[orig_patent_app_number] => 12464788
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/464788 | CARBOHYDRATE BINDING MODULE AND USE THEREOF | May 11, 2009 | Abandoned |
Array
(
[id] => 8834301
[patent_doc_number] => 08450056
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-05-28
[patent_title] => 'Arrayed imaging reflectometry (AIR) sensor chip comprising virus-like particles suitable for the detection of antiviral immune responses'
[patent_app_type] => utility
[patent_app_number] => 12/434298
[patent_app_country] => US
[patent_app_date] => 2009-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 9
[patent_no_of_words] => 9313
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12434298
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/434298 | Arrayed imaging reflectometry (AIR) sensor chip comprising virus-like particles suitable for the detection of antiviral immune responses | Apr 30, 2009 | Issued |
Array
(
[id] => 8920688
[patent_doc_number] => 08486619
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-07-16
[patent_title] => 'Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses'
[patent_app_type] => utility
[patent_app_number] => 12/434438
[patent_app_country] => US
[patent_app_date] => 2009-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 22
[patent_no_of_words] => 13956
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 142
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12434438
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/434438 | Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses | Apr 30, 2009 | Issued |
Array
(
[id] => 5936014
[patent_doc_number] => 20110212118
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-09-01
[patent_title] => 'TAT Protein for preventing or treating AIDS'
[patent_app_type] => utility
[patent_app_number] => 12/989165
[patent_app_country] => US
[patent_app_date] => 2009-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 14478
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0212/20110212118.pdf
[firstpage_image] =>[orig_patent_app_number] => 12989165
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/989165 | Modified Tat Oyi protein with enhanced immunogenicity | Apr 21, 2009 | Issued |
Array
(
[id] => 5936014
[patent_doc_number] => 20110212118
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-09-01
[patent_title] => 'TAT Protein for preventing or treating AIDS'
[patent_app_type] => utility
[patent_app_number] => 12/989165
[patent_app_country] => US
[patent_app_date] => 2009-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 14478
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0212/20110212118.pdf
[firstpage_image] =>[orig_patent_app_number] => 12989165
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/989165 | Modified Tat Oyi protein with enhanced immunogenicity | Apr 21, 2009 | Issued |
Array
(
[id] => 7487513
[patent_doc_number] => 20110236409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-09-29
[patent_title] => 'OVERLAPPING PEPTIDES FROM VARIABLE ANTIGENS, T CELL POPULATIONS AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/936370
[patent_app_country] => US
[patent_app_date] => 2009-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 12701
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0236/20110236409.pdf
[firstpage_image] =>[orig_patent_app_number] => 12936370
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/936370 | OVERLAPPING PEPTIDES FROM VARIABLE ANTIGENS, T CELL POPULATIONS AND USES THEREOF | Mar 29, 2009 | Abandoned |
Array
(
[id] => 6024305
[patent_doc_number] => 20110052631
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-03-03
[patent_title] => 'INDUCTION OF PROLIFERATION, EFFECTOR MOLECULE EXPRESSION, AND CYTOLYTIC CAPACITY OF HIV-SPECIFIC CD8+ T CELLS'
[patent_app_type] => utility
[patent_app_number] => 12/934522
[patent_app_country] => US
[patent_app_date] => 2009-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 15468
[patent_no_of_claims] => 42
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0052/20110052631.pdf
[firstpage_image] =>[orig_patent_app_number] => 12934522
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/934522 | INDUCTION OF PROLIFERATION, EFFECTOR MOLECULE EXPRESSION, AND CYTOLYTIC CAPACITY OF HIV-SPECIFIC CD8+ T CELLS | Mar 24, 2009 | Abandoned |
Array
(
[id] => 8188356
[patent_doc_number] => 08182820
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-05-22
[patent_title] => 'Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens'
[patent_app_type] => utility
[patent_app_number] => 12/407730
[patent_app_country] => US
[patent_app_date] => 2009-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 42
[patent_no_of_words] => 14235
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/182/08182820.pdf
[firstpage_image] =>[orig_patent_app_number] => 12407730
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/407730 | Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens | Mar 18, 2009 | Issued |
Array
(
[id] => 5342395
[patent_doc_number] => 20090181045
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-07-16
[patent_title] => 'TAT-BASED VACCINE COMPOSITIONS AND METHODS OF MAKING AND USING SAME'
[patent_app_type] => utility
[patent_app_number] => 12/405086
[patent_app_country] => US
[patent_app_date] => 2009-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 9687
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0181/20090181045.pdf
[firstpage_image] =>[orig_patent_app_number] => 12405086
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/405086 | TAT-BASED VACCINE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | Mar 15, 2009 | Abandoned |
Array
(
[id] => 6245989
[patent_doc_number] => 20100136098
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-06-03
[patent_title] => 'AVIAN INFLUENZA VACCINE'
[patent_app_type] => utility
[patent_app_number] => 12/400269
[patent_app_country] => US
[patent_app_date] => 2009-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11981
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0136/20100136098.pdf
[firstpage_image] =>[orig_patent_app_number] => 12400269
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/400269 | Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain | Mar 8, 2009 | Issued |
Array
(
[id] => 7514933
[patent_doc_number] => 08039003
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-10-18
[patent_title] => 'Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis'
[patent_app_type] => utility
[patent_app_number] => 12/396376
[patent_app_country] => US
[patent_app_date] => 2009-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 14
[patent_no_of_words] => 53366
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/039/08039003.pdf
[firstpage_image] =>[orig_patent_app_number] => 12396376
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/396376 | Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis | Mar 1, 2009 | Issued |
Array
(
[id] => 5479628
[patent_doc_number] => 20090202585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-08-13
[patent_title] => 'TAT-BASED TOLEROGEN COMPOSITIONS AND METHODS FOR MAKING AND USING SAME'
[patent_app_type] => utility
[patent_app_number] => 12/395975
[patent_app_country] => US
[patent_app_date] => 2009-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 11431
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0202/20090202585.pdf
[firstpage_image] =>[orig_patent_app_number] => 12395975
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/395975 | TAT-BASED TOLEROGEN COMPOSITIONS AND METHODS FOR MAKING AND USING SAME | Mar 1, 2009 | Abandoned |
Array
(
[id] => 6323672
[patent_doc_number] => 20100196992
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-08-05
[patent_title] => 'INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA'
[patent_app_type] => utility
[patent_app_number] => 12/393861
[patent_app_country] => US
[patent_app_date] => 2009-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 19149
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0196/20100196992.pdf
[firstpage_image] =>[orig_patent_app_number] => 12393861
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/393861 | Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) | Feb 25, 2009 | Issued |
Array
(
[id] => 6228925
[patent_doc_number] => 20100183663
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-07-22
[patent_title] => 'INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA'
[patent_app_type] => utility
[patent_app_number] => 12/393840
[patent_app_country] => US
[patent_app_date] => 2009-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 19124
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0183/20100183663.pdf
[firstpage_image] =>[orig_patent_app_number] => 12393840
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/393840 | Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) | Feb 25, 2009 | Issued |